GLP-1 Receptor Agonists for Hepatic Steatosis and Fibrosis in Type 2  Diabetes with NAFLD.

Mishal Rizwan, Alveena Fareed, Sarah Khan, Ali Hassan, FNU Nikeeta, Haleema Hammad

GLP-1 Receptor Agonists for Hepatic Steatosis and Fibrosis in Type 2 Diabetes with NAFLD.

Authors

Mishal Rizwan, Alveena Fareed, Sarah Khan, Ali Hassan, FNU Nikeeta, Haleema Hammad

Keywords:

GLP-1 receptor agonist; MRI-PDFF; liver stiffness

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may attenuate hepatic steatosis andmodify fibrosis risk in type 2 diabetes mellitus (T2D) with nonalcoholic fatty liver disease. Thisprospective, parallel-group study evaluated once-weekly semaglutide added to standard diabetes care versus standard care alone over 48 weeks in adults with T2D

References

Newsome PN, Buchholtz K, Cusi K, et al. Subcutaneous semaglutide in biopsy-proven steatohepatitis: randomized trial showing higher NASH resolution rates versus placebo (2021). DOI: 10.1056/NEJMoa2028395. (New England Journal of Medicine)

Zhu K, et al. Efficacy and safety of semaglutide in NAFLD: systematic review and metaanalysis (2023). PMID: 37827861; PMCID: PMC10600803. (PMC)

Downloads

Published

2025-08-30

How to Cite

Mishal Rizwan, Alveena Fareed, Sarah Khan, Ali Hassan, FNU Nikeeta, Haleema Hammad. (2025). GLP-1 Receptor Agonists for Hepatic Steatosis and Fibrosis in Type 2 Diabetes with NAFLD . International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 1632–1640. Retrieved from https://www.ijprt.org/index.php/pub/article/view/942